Search Results
Results found for "chronic pain"
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
Her choice to stay in academia isn’t about rejecting industry—it’s about embracing the freedom to chase Like many young scientists, she explored different paths and gained industry experience before realizing whether to stay in academia or move into industry, Catherine speaks with unusual clarity about her choice
- Better GPCR Drug Discovery Decisions Start With Structured Learning
What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
In This Session, You’ll Gain Clarity on how ADME governs translational success A deeper understanding in vitro permeation assays  that enable early iteration Absorption failures are rarely about route choice
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
Deep mutational scanning, for instance, is gaining popularity as a strategy due to its ability to comprehensively
- Curve Shifts Don’t Lie, But Your Eyes Might
In This Session, You’ll Gain: ✅ The ability to calculate how many replicates you really  need for 95% By comparing two means (paired or unpaired) you’ll learn whether the divergence is genuine or whether
- Your GPCR Program Decisions Depend on Good Data Interpretation
GPCR Premium Members this week gain curated, early access to: Industry insights : GPCRs and mRNA in drug At Alkermes, Sokhom Pin built an in vitro pharmacology group from scratch—not just a lab, but a culture
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
In this session, you’ll gain: A clear conceptual map of Schild analysis and its origins.
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic In this session, you’ll gain: ✅Clarity on Definitions:  What truly distinguishes orthosteric from allosteric
- đź“° GPCR Weekly News, March 4 to 10, 2024
Gain invaluable skills in data analysis under Dr. Hoare's expert guidance.
- Why Opposing Processes Matter for Your Next GPCR Drug
In this session, you’ll gain: ✅ A mental model you can trust  for predicting how GPCR ligands behave
- Quantifying Receptor Selectivity in Modern Drug Discovery
In this session, you’ll gain: A framework for cancelling cell effects to isolate true receptor selectivity
- đź“° GPCR Weekly News - January 9 to 15, 2023
Mandibulofacial dysostosis with alopecia results from gain-of-ETAR function via allosteric effects on
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! âť„ Dec 2 - 8, 2024
As a Premium Member, you gain exclusive access to this incredible treasure trove we've amassed over the
- Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted drug discovery
ERK activation pathways can be categorised into two main sub-pathways based on their subcellular localisation The choice of pathway can result in different cellular responses, underscoring the criticality of precise
- đź“° GPCR Weekly News, February 13 to 19, 2023
Mandibulofacial dysostosis with alopecia results from ETAR gain-of-function mutations via allosteric
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
remaining non-sensory receptors, with functions more readily linked to pathology, are currently the main cell surface, or because they have an enhanced capacity to elicit receptor internalization, thereby gaining 17706–17711. https://doi.org/10.1073/pnas.0805098105 · Development and use of new technology to gain
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
In this lesson, you'll gain: ✅ Clarity on what “irreversible” really means  in kinetic and pharmacologic It’s a design space , not a binary choice, and penetration is just the beginning.
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
In this course, you’ll gain: ✅ How assay volume control  alters receptor sensitivity and what that
- From DNA day to GPCR genomics
The G-protein-coupled receptors in the human genome form five main families.
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
This concept is gaining significant attention in drug discovery, especially in the context of G protein-coupled
- đź“° GPCR Weekly News, September 25 to October 1, 2023
Subscribe now to gain access to exclusive insights from Dr. GPCR Newsletter!
- From Snapshots to Predictions: Why Mechanism of Action Matters
In This Session, You’ll Gain: ✅ How to turn descriptive snapshots into predictive insights ✅ Tools to What looked like four conflicting behaviors turned out to be one coherent mechanism , hidden in plain Unlock “Mechanism of Action” now Only in Terry’s Corner  Why Terry’s Corner When early choices determine
- đź“° GPCR Weekly News, March 11 to 17, 2024
Hoare's expert guidance, you will gain invaluable skills in data analysis.
- đź“° GPCR Weekly News, August 28 to September 3, 2023
GPCR Newsletter to gain access to further insights!
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
animals — a milestone that demonstrated just how powerful well-engineered chemical tools can be when paired JB gained a grounded understanding of tissue heterogeneity, signal variability, and the biology that
- 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Gain access to over 500 minutes of recorded classes in our GPCR courses  taught by Drs.
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
In this session, you’ll gain: Why saturation and displacement assays fail when protein stoichiometry
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
In this session, you’ll gain: How system sensitivity transforms potency, efficacy, and agonist classification
- From Failed Experiments to Predictive GPCR Models
His introduction came through a practical suggestion: explore a new protein family that was gaining traction




















